Trial Profile
Safety Assessment of Repeated Administration of a Fully Human Monoclonal Antibody of RNAKL (TK006) in Patients With Breast Cancer-related Bone Metastases
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 05 Apr 2018 New trial record